

Durham Research Online

Deposited in DRO:

06 February 2018

Version of attached file:

Accepted Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

Baumann, Marcus and Baxendale, Ian R (2018) 'Diastereoselective synthesis and diversification of highly functionalized cyclopentanones.', *Synthesis.*, 50 (04). pp. 753-759.

Further information on publisher's website:

<https://doi.org/10.1055/s-0036-1591745>

Publisher's copyright statement:

© Georg Thieme Verlag

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.


Diastereoselective Synthesis and Diversification of Highly Functionalized Cyclopentanones

Marcus Baumann^{*a}
Ilan R. Baxendale^a

^a Department of Chemistry, University of Durham, South Road,
DH1 3LE, Durham, United Kingdom

marcus.baumann@durham.ac.uk

[Click here to insert a dedication.](#)




Received:
Accepted:
Published online:
DOI:

Abstract An efficient entry into highly substituted cyclopentanones is presented based on functionalizing cyclopentenones by means of an aza-Michael reaction with different aniline nucleophiles. The excellent diastereoselectivity of this process is ascribed to H-bonding between a tertiary alcohol and the incoming nucleophiles. Additionally, the functionalization of the parent cyclopentenones via the Baylis-Hillman reaction is demonstrated. Together, these transformations showcase the elaboration of a simple precursor by installation of versatile functionalities at either the α - or β -position of the embedded enone and thus represent valuable methods for the construction of diversely functionalized cyclopentanones.

Key words cyclopentanone, aza-Michael reaction, Baylis-Hillman reaction, diastereoselectivity, H-bonding

The efficient assembly of suitably functionalized three-dimensional building blocks has in recent years gained increasing interest as it allows for the generation of structures occupying new chemical and biological space.¹ Moreover, the sustainability of such processes is of increasing importance being a key feature that enables the reliable and future-proofed construction of such chiral building blocks.² Together with the operational simplicity and robustness modern synthesis efforts aim to adhere to green chemistry principles whenever possible.³ In a recent synthesis program, we have for instance developed a flow process for converting bioderived D-glucono-1,5-lactone **1** into chiral cyclopentenone **4** in continuous mode (Scheme 1).⁴



Scheme 1: Continuous flow synthesis of cyclopentenone **4**.

Highlights of this work included the application of powder dosing equipment and counter-current extraction modules allowing for the continuous production of **4** and selected key intermediates on large scale (>100 g). Furthermore, the successful implication of this route avoided the use of excessive or hazardous solvents and reagents as well as the need for chromatographic purifications. With a robust route to cyclopentenone **4** in hand we subsequently wished to study its conversion into further products of interest, especially those decorated with pendant amine functionalities. Crucially, we envisaged such amino-hydroxy cyclopentanones to be worthwhile targets as related structures such as (–)-agelastatin A (**5**), pactamycin (**6**), or peramivir (**7**) are known to possess interesting biological properties. In addition, as highly efficient and modern routes towards such structures have been developed recently,⁵ providing a rapid access to simplified derivatives is becoming equally desirable (Figure 1).





Figure 1: Structures of bioactive cyclopentanes.


We commenced our study by investigating the conjugate addition of different anilines **8** to cyclopentenone **4**. Screening different solvents it was found that polar, aprotic solvents such as MeCN, dioxane or DMF were preferred over non-polar solvents (DCM, toluene, hexanes), especially when high concentrations of 2–4 M were employed. We thus opted for MeCN as a suitable and benign solvent and subsequently studied the effect of different temperatures keeping the concentration at 3 M throughout. It

was quickly established, that temperatures of 50–75 °C gave full conversion within 6–12 h whereas lower temperatures significantly slowed down the reaction. We therefore identified ideal conditions to be the use of MeCN with high concentration of both substrates (**4** and **8**, 1:1 ratio, 3 M) at a reaction temperature of 70 °C (Scheme 2).



Scheme 2: Optimized conditions for preparing aniline adducts.

With these conditions in hand we next investigated the reaction of a series of anilines with substrate **4** aiming to establish the generality of this approach. We were thus pleased to see the smooth reaction of a variety of anilines under the established reaction conditions. As expected, electron-rich anilines gave faster reactions than neutral systems, whereas electron-poor anilines ($R = \text{CN}, \text{NO}_2$) gave very low conversion (~10%) to the desired product after 12–24 h. It was also found that secondary anilines were poor reaction partners due to steric hindrance, typically resulting in low conversion only (5–10% after 24 h). Importantly, a variety of different substitution patterns on the arene moiety of primary anilines was tolerated allowing for the creation of diversely functionalized systems. In addition, heteroaryl amines such as those based on pyridines, as well as biaryl amines are well tolerated in this transformation furnishing the desired adducts in good to excellent isolated yields after purification via column chromatography (Scheme 3).



Scheme 3: Substrate scope for products **9a–i**.

Crucially, these products were obtained as single diastereomers prompting us to investigate the origin of this stereoselectivity. We therefore crystallized products **9e** and **9g** allowing for single

crystal diffraction experiments to be performed. These structures both indicate a syn-relationship between the tertiary alcohol and the amine functionality (Figure 2).⁶





Figure 2: X-ray structures of **9e** (left) and **9g** (right).


We reasoned that this diastereoselectivity is the result of hydrogen bonding where the hydroxyl group directs the incoming amine nucleophile in a syn-fashion. It appears that this hydrogen bonding is not disturbed by additional hydrogen bond acceptors such as the pyridine nitrogen as evidenced in structure **9g**.

Having accomplished the efficient functionalization of the β -position of the cyclopentenone building block **4**, we furthermore wished to establish whether the adjacent α -position is amenable to effective derivatization. To this end we opted to exploit the reaction of **4** with a small selection of benzaldehydes (**10**) via a Baylis-Hillman reaction. After screening different solvents, it was found that a mixture of chloroform and THF (1:1 v/v, 1.5 M) worked best in combination with DABCO as a catalyst (25 mol%) to give the desired reaction products **11** (Scheme 4). Using ¹H-NMR as a reliable technique to establish reaction progress allowed the identification of suitable conditions that promoted full conversion of all substrates within 10 h at 40 °C.



Scheme 4: Baylis-Hillman reaction of **4** and benzaldehydes **10**.

Furthermore, we noticed that under the chosen reaction conditions cyclopentenone **4** is a fluxional species that undergoes additional transformations such as the formation of the isolable rearrangement structure **4c** which likely results from an allylic transposition reaction of **4** via intermediate **4b** (Scheme 5).



Scheme 5: Reaction pathways of cyclopentenone **4**.

This material (**4c**) was identified based on a combination of ^1H -NMR and ^{13}C -NMR techniques and did not form unless all components were present in the reaction mixture (**4**, **10** and DABCO). Based on this, we suggest a mechanism in which the aldehyde component is aiding in the allylic transposition by forming a covalent adduct **4a** en route to intermediate **4b** (Scheme 5). In addition, mixtures of **4** and **4c** can be isolated after column chromatography for further analysis (see SI for details). However, as the desired Baylis-Hillman products **11** were obtained as principle products from this reaction, we surmise that **4b** co-exists in an inconsequential equilibrium with **4** from which only **4** is partaking in the overall transformation. To confirm the connectivity of products **11** we secured an X-ray crystal structure of derivative **11a**. In agreement with NMR-spectroscopy the X-ray diffraction experiments confirmed that these products (**11a-11d**) are formed as mixtures of diastereoisomers (d.r. ~1:1)⁷ indicating that in this instance the more remote tertiary alcohol is not controlling the stereochemistry (Figure 3).




Figure 3: Baylis-Hillman products and X-ray structure of **11 a**.

In summary, we have developed efficient routes for the functionalization of a versatile cyclopentenone building block that was previously accessed via a continuous flow sequence from D-glucono-1,5-lactone. Initially, we investigated the aza-Michael addition of different anilines resulting in the diastereoselective formation of the corresponding adducts. We furthermore demonstrated the functionalization of the α -position of the cyclopentenone substrate via a Baylis-Hillman reaction. Whereas the desired products were obtained as mixtures of diastereoisomers, we discovered a complementary allylic transposition pathway, that appears to be mediated by the aldehyde substrate which we will investigate in due course.

The experimental section has no title; please leave this line here.

Unless otherwise stated, all solvents were purchased from Fisher Scientific and used without further purification. Substrates and reagents were purchased from Alfa Aesar or Sigma Aldrich and used as received.

^1H -NMR spectra were recorded on a Bruker Avance-400 instrument and are reported relative to residual solvent: CHCl_3 (δ 7.26 ppm) or DMSO (δ 2.50 ppm). ^{13}C -NMR spectra were recorded on the same instrument and are reported relative to CHCl_3 (δ 77.16 ppm) or DMSO (δ 39.52 ppm). Data for ^1H -NMR are reported as follows: chemical shift (δ /ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, br. s = broad singlet, app = apparent. Data for ^{13}C -NMR are

reported in terms of chemical shift (δ /ppm) and multiplicity (C, CH, CH_2 or CH_3). Data for ^{19}F -NMR were recorded on the above instrument at a frequency of 376 MHz using CFCl_3 as external standard. DEPT-135, COSY, HSQC, HMBC and NOESY experiments were used in the structural assignment. IR spectra were obtained by use of a Perkin Elmer RX1 spectrometer (neat, ATR sampling) with the intensities of the characteristic signals being reported as weak (w, <20% of tallest signal), medium (m, 21-70% of tallest signal) or strong (s, >71% of tallest signal). Low and high-resolution mass spectrometry was performed using the indicated techniques on either Waters LCT Premier XE or Waters TQD instruments equipped with Acquity UPLC and a lock-mass electrospray ion source. Melting points were recorded on an Optimelt automated melting point system with a heating rate of $1^\circ\text{C}/\text{min}$ and are uncorrected.

Procedures

For the synthesis of amino-hydroxycyclopentanones **9a-9i** the desired aniline (1 mmol, 1.0 equiv.) was added to a solution of cyclopentanone **4** (1 mmol, 1.0 equiv.; 2 M, MeCN). The resulting reaction mixture was heated at 75°C and monitored by ^1H -NMR. Once complete conversion of substrates was observed (6-12 h) the reaction mixture was evaporated and purified by silica column chromatography using EtOAc/hexanes (10-30% EtOAc) as solvent system. After evaporation of the volatiles the desired products were typically isolated as yellow oils that solidified upon standing.

Rac-(1*S*,2*R*)-Methyl 2-((4-chlorophenyl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (**9a**)

IR (neat): 3386 (m), 2955 (w), 1737 (s), 1599 (s), 1492 (s), 1398 (m), 1316 (m), 1277 (m), 1234 (s), 1179 (s), 1091 (s), 1029 (m), 818 (s), 753 (s), 501 (m) cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ = 7.10 (d, J = 8.9 Hz, 2H), 6.55 (d, J = 8.9 Hz, 2H), 4.48 (dd, J = 10.9, 7.9 Hz, 1H), 3.88 (br s, 1H), 3.74 (s, 3H), 2.79-2.89 (m, 2H), 2.61 (d, J = 18.2 Hz, 1H), 2.30 (ddd, J = 18.3, 10.9, 1.8 Hz, 1H).

^{13}C NMR (CDCl_3 , 101 MHz): δ = 210.6 (C), 174.0 (C), 144.9 (C), 129.2 (2CH), 123.4 (C), 115.1 (2CH), 78.7 (C), 57.4 (CH), 53.6 (CH_3), 50.7 (CH_2), 42.2 (CH_2).

HRMS (ASAP): m/z [$\text{M} + \text{H}$]⁺ calcd for $\text{C}_{13}\text{H}_{15}\text{NO}_4\text{Cl}$: 284.0690; found: 284.0688.

Rac-(1*S*,2*R*)-Methyl 2-((3-bromophenyl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (**9b**)

IR (neat): 3392 (m), 2955 (w), 1737 (s), 1595 (s), 1505 (m), 1481 (m), 1266 (m), 1235 (s), 1198 (s), 1164 (s), 1089 (s), 987 (s), 756 (s), 734 (s), 682 (m), 480 (m) cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ = 7.01 (t, J = 8.0 Hz, 1H), 6.86 (ddd, J = 7.8, 1.8, 0.9 Hz, 1H), 6.77 (t, J = 2.1 Hz, 1H), 6.54 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H), 4.51 (dd, J = 11.0, 7.9 Hz, 1H), 4.26 (br s, 1H), 3.80 (s, 3H), 2.81-2.92 (m, 2H), 2.62 (d, J = 18.2 Hz, 1H), 2.32 (ddd, J = 18.2, 10.9, 1.8 Hz, 1H).

^{13}C NMR (CDCl_3 , 101 MHz): δ = 210.3 (C), 173.9 (C), 147.6 (C), 130.7 (CH), 123.4 (C), 121.6 (CH), 116.3 (CH), 112.9 (CH), 78.6 (C), 56.9 (CH), 53.8 (CH_3), 50.6 (CH_2), 42.3 (CH_2).

HRMS (ASAP): m/z [$\text{M} + \text{H}$]⁺ calcd for $\text{C}_{13}\text{H}_{15}\text{NO}_4\text{Br}$: 328.0184; found: 328.0172.

Rac-(1*S*,2*R*)-Methyl 2-((4-bromophenyl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (**9c**)

IR (neat): 3476 (m), 3383 (m), 2957 (w), 1737 (s), 1593 (s), 1489 (s), 1437 (m), 1397 (m), 1316 (m), 1278 (m), 1235 (s), 1179 (s), 1074 (m), 908 (s), 815 (s), 728 (s), 648 (m), 499 (m) cm^{-1} .

^1H NMR (CDCl_3 , 400 MHz): δ = 7.26 (d, J = 8.0 Hz, 2H), 6.53 (d, J = 8.0 Hz, 2H), 4.51 (app q, J = 8.7 Hz, 1H), 4.25 (d, J = 9.1 Hz, 1H), 3.83 (br s, 1H), 3.78 (s, 3H), 2.83-2.92 (m, 2H), 2.64 (d, J = 18.3 Hz, 1H), 2.33 (ddd, J = 18.3, 10.8, 1.8 Hz, 1H).

¹³C NMR (CDCl₃, 101 MHz): δ = 210.4 (C), 174.0 (C), 145.3 (C), 132.1 (2CH), 115.6 (2CH), 110.5 (C), 78.7 (C), 57.2 (CH), 53.7 (CH₃), 50.7 (CH₂), 42.3 (CH₂).

HRMS (AP): *m/z* [M + H]⁺ calcd for C₁₃H₁₅NO₄Br: 328.0184; found: 328.0193.

***Rac*-(1*S*,2*R*)-Methyl 2-(*m*-tolylamino)-1-hydroxy-4-oxocyclopentanecarboxylate (9d)**

IR (neat): 3391 (m), 2959 (w), 1739 (s), 1606 (m), 1490 (m), 1437 (m), 1235 (m), 1167 (s), 1096 (m), 1030 (m), 909 (s), 772 (s), 728 (s), 692 (s), 648 (m), 440 (m) cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ = 7.07 (app t, *J* = 7.6 Hz, 1H), 6.60 (d, *J* = 7.6 Hz, 1H), 6.40-6.50 (m, 2H), 4.54 (app q, *J* = 10.0 Hz, 1H), 4.09 (d, *J* = 9.6 Hz, 1H), 3.75 (s, 3H), 2.80-2.92 (m, 2H), 2.65 (d, *J* = 18.4 Hz, 1H), 2.32 (ddd, *J* = 18.4, 11.0, 1.8 Hz, 1H), 2.27 (s, 3H).

¹³C NMR (CDCl₃, 101 MHz): δ = 210.8 (C), 174.1 (C), 146.2 (C), 139.2 (C), 129.3 (CH), 119.8 (CH), 114.8 (CH), 111.1 (CH), 78.8 (C), 57.4 (CH), 53.5 (CH₃), 50.6 (CH₂), 42.5 (CH₂), 21.6 (CH₃).

HRMS (ES): *m/z* [M + H]⁺ calcd for C₁₄H₁₈NO₄: 264.1236; found: 264.1237.

***Rac*-(1*S*,2*R*)-Methyl 2-((3-methoxyphenyl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (9e)**

IR (neat): 3437 (m), 3359 (m), 2963 (w), 1733 (s), 1595 (s), 1492 (m), 1230 (s), 1172 (s), 1126 (s), 1026 (s), 973 (m), 839 (s), 774 (m), 756 (m), 692 (m), 498 (m) cm⁻¹.

¹H NMR (CDCl₃, 600 MHz): δ = 7.06 (app t, *J* = 8.2 Hz, 1H), 6.30 (ddd, *J* = 8.2, 2.3, 0.8 Hz, 1H), 6.23 (ddd, *J* = 8.2, 2.3, 0.8 Hz, 1H), 6.18 (app t, *J* = 2.3 Hz, 1H), 4.51 (app t, *J* = 9.4 Hz, 1H), 4.17 (s, 1H), 3.77 (s, 1H), 3.75 (s, 3H), 3.74 (s, 3H), 2.82-2.88 (m, 2H), 2.61 (ddd, *J* = 18.2, 1.9, 0.8 Hz, 1H), 2.30 (ddd, *J* = 18.2, 10.8, 1.9 Hz, 1H).

¹³C NMR (CDCl₃, 151 MHz): δ = 210.7 (C), 174.1 (C), 160.8 (C), 147.5 (C), 130.2 (CH), 106.8 (CH), 103.8 (CH), 100.2 (CH), 78.8 (C), 57.2 (CH), 55.1 (CH₃), 53.6 (CH₃), 50.6 (CH₂), 42.4 (CH₂).

HRMS (ES): *m/z* [M + H]⁺ calcd for C₁₄H₁₈NO₅: 280.1185; found: 280.1163.

***Rac*-(1*S*,2*R*)-Methyl 2-((4-chloro-2,5-dimethoxyphenyl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (9f)**

IR (neat): 3395 (w), 2957 (w), 1747 (s), 1596 (m), 1515 (s), 1450 (s), 1398 (s), 1207 (s), 1159 (s), 1031 (s), 910 (m), 848 (m), 796 (m), 728 (s), 649 (m) cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ = 6.76 (s, 1H), 6.31 (s, 1H), 4.51 (dd, *J* = 11.1, 7.9 Hz, 1H), 3.82 (s, 3H), 3.80 (s, 3H), 3.70 (s, 3H), 2.78-2.91 (m, 2H), 2.65 (ddd, *J* = 18.2, 1.8, 0.9 Hz, 1H), 2.32-2.43 (m, 1H).

¹³C NMR (CDCl₃, 101 MHz): δ = 210.4 (C), 174.0 (C), 149.6 (C), 141.7 (C), 135.5 (C), 112.4 (CH), 110.3 (C), 98.6 (CH), 78.7 (C), 57.8 (CH), 57.2 (CH₃), 56.2 (CH₃), 53.5 (CH₃), 50.6 (CH₂), 42.4 (CH₂).

HRMS (ES): *m/z* [M + H]⁺ calcd for C₁₅H₁₉NO₆Cl: 344.0901; found: 344.0900.

***Rac*-(1*S*,2*R*)-Methyl 2-((5-bromopyridin-3-yl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (9g)**

IR (neat): 3358 (m), 2926 (m), 1739 (s), 1582 (s), 1518 (m), 1448 (m), 1234 (s), 1201 (s), 1161 (s), 1095 (s), 1031 (m), 1006 (m), 753 (s), 695 (m) cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ = 8.02 (d, *J* = 1.9 Hz, 1H), 7.92 (d, *J* = 2.6 Hz, 1H), 7.07 (dd, *J* = 2.6, 1.9 Hz, 1H), 4.46-4.56 (m, 2H), 3.82 (s, 3H), 2.81-2.92 (m, 2H), 2.64 (ddd, *J* = 18.2, 19, 0.9 Hz, 1H), 2.29-2.41 (m, 1H).

¹³C NMR (CDCl₃, 101 MHz): δ = 209.6 (C), 173.7 (C), 143.5 (C), 140.2 (CH), 134.9 (CH), 121.9 (CH), 121.1 (C), 78.6 (C), 56.4 (CH), 53.8 (CH₃), 50.7 (CH₂), 42.0 (CH₂).

HRMS (ASAP): *m/z* [M + H]⁺ calcd for C₁₂H₁₄N₂O₄Br: 329.0137; found: 329.0122.

***Rac*-(1*S*,2*R*)-Methyl 2-((3-(6-methoxypyridin-3-yl)phenyl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (9h)**

IR (neat): 3383 (w), 2952 (w), 1740 (s), 1604 (s), 1481 (s), 1366 (m), 1283 (s), 1235 (s), 1173 (s), 1021 (s), 832 (m), 752 (s), 697 (m), 609 (m) cm⁻¹.

¹H NMR (CDCl₃, 400 MHz): δ = 8.33 (dd, *J* = 2.6, 0.7 Hz, 1H), 7.72 (dd, *J* = 8.6, 2.6 Hz, 1H), 7.21 (app t, *J* = 7.8 Hz, 1H), 6.85-6.90 (m, 1H), 6.73-6.80 (m, 2H), 6.60 (ddd, *J* = 8.2, 2.4, 0.9 Hz, 1H), 4.60 (dd, *J* = 10.8, 7.8 Hz, 1H), 4.41 (br s, 1H), 4.16 (br s, 1H), 3.67 (s, 3H), 3.67 (s, 3H), 2.82-2.94 (m, 2H), 2.59-2.67 (m, 1H), 2.35 (ddd, *J* = 18.8, 10.8, 1.8 Hz, 1H).

¹³C NMR (CDCl₃, 101 MHz): δ = 211.0 (C), 174.0 (C), 163.6 (C), 146.8 (C), 144.9 (CH), 139.1 (C), 137.5 (CH), 130.1 (C), 130.0 (CH), 117.2 (CH), 112.9 (CH), 112.2 (CH), 110.6 (CH), 78.9 (C), 57.3 (CH), 53.6 (CH₃), 53.5 (CH₃), 50.7 (CH₂), 42.3 (CH₂).

HRMS (ASAP): *m/z* [M + H]⁺ calcd for C₁₉H₂₁N₂O₅: 357.1450; found: 357.1452.

***Rac*-(1*S*,2*R*)-Methyl 2-((3-fluoro-4-methylphenyl)amino)-1-hydroxy-4-oxocyclopentanecarboxylate (9i)**

IR (neat): 3384 (m), 2956 (w), 1736 (s), 1633 (s), 1589 (m), 1516 (s), 1438 (m), 1326 (m), 1266 (m), 1235 (s), 1159 (s), 1114 (s), 1029 (m), 838 (m), 803 (m), 735 (s), 626 (m), 454 (m) cm⁻¹.

¹H NMR (CDCl₃, 600 MHz): δ = 6.90-6.96 (m, 1H), 6.29-6.33 (m, 2H), 4.46 (ddd, *J* = 11.0, 10.0, 7.9 Hz, 1H), 4.11 (d, *J* = 8.8 Hz, 1H), 3.77 (s, 3H), 3.70 (s, 1H), 2.82-2.88 (m, 2H), 2.61 (ddd, *J* = 18.3, 1.9, 0.9 Hz, 1H), 2.27-2.33 (m, 1H), 2.13 (d, *J* = 1.3 Hz, 3H).

¹³C NMR (CDCl₃, 151 MHz): δ = 210.3 (C), 174.0 (C), 161.9 (d, *J* = 243 Hz, C), 145.7 (d, *J* = 11 Hz, C), 131.9 (d, *J* = 8 Hz, CH), 114.5 (d, *J* = 18 Hz, C), 109.7 (d, *J* = 2 Hz, CH), 100.9 (d, *J* = 26 Hz, CH), 78.6 (C), 57.4 (CH), 53.6 (CH₃), 50.6 (CH₂), 42.3 (CH₂), 13.6 (CH₃).

¹⁹F NMR (CDCl₃, 376 MHz): δ = -116.3 (s).

HRMS (ASAP): *m/z* [M + H]⁺ calcd for C₁₄H₁₇NO₄F: 282.1142; found: 282.1158.

Procedures

For the synthesis of Baylis-Hillman adducts **11a-11d** cyclopentenone **4** (0.8 mmol, 1.0 equiv.), DABCO (0.2 mmol, 0.25 equiv.) and the aldehyde component (1.0 mmol, 1.25 equiv.) were dissolved in a mixture of THF and CHCl₃ (1:1 v/v, 1.5 M) and stirred at 40 °C for 10 h. After completion of the reaction was indicated by tlc (20% EtOAc/hexanes) the solvents were evaporated and the crude product was purified by silica column chromatography 10-30% EtOAc/hexanes) to yield a mixture of co-polar reaction products. It was found possible to crystallize the less soluble diastereomer of **11** using CHCl₃ or Et₂O as solvent.

Methyl 3-((4-bromophenyl)(hydroxy)methyl)-1-hydroxy-4-cyclopent-2-enecarboxylate (11a)

IR (neat): 3418 (br), 2956 (w), 1714 (s), 1488 (m), 1437 (m), 1402 (m), 1258 (s), 1198 (s), 1171 (s), 1071 (s), 1011 (m), 832 (m) cm⁻¹.

Diastereomer A: ¹H NMR (CDCl₃, 400 MHz): δ = 7.47 (d, *J* = 8.4 Hz, 2H), 7.25 (d, *J* = 8.4 Hz, 2H), 6.98 (s, 1H), 3.81 (s, 3H), 2.98 (br s, 1H), 2.95 (d, *J* = 18.4 Hz, 1H), 2.60 (d, *J* = 18.4 Hz, 1H). ¹³C NMR (CDCl₃, 176 MHz): δ = 203.9 (C), 173.9 (C), 153.8 (CH), 149.2 (C), 139.1 (C), 131.8 (2CH), 128.3 (2CH), 122.3 (C), 76.9 (C), 68.9 (CH), 54.0 (CH₂), 48.3 (CH₂). *Diastereomer B*: ¹H NMR (CDCl₃, 400 MHz): δ = 7.47 (d, *J* = 8.4 Hz, 2H), 7.24 (d, *J* = 8.4 Hz, 2H), 6.98 (s, 1H), 5.52 (s, 1H), 3.79 (s, 3H), 3.03 (br s, 1H), 2.92 (d, *J* = 18.4 Hz, 1H), 2.65 (d, *J* = 18.4 Hz, 1H). ¹³C NMR (CDCl₃, 176 MHz): δ = 204.1 (C), 173.8 (C), 154.2 (CH), 149.1 (C), 138.3 (C), 131.8 (2CH), 128.3 (2CH), 122.3 (C), 77.0 (C), 68.9 (CH), 53.9 (CH₃), 48.2 (CH₂).

HRMS (ASAP): *m/z* [M - OH]⁺ calcd for C₁₄H₁₂BrO₄: 322.9919; found: 322.9932.

Methyl 3-((3-fluorophenyl)(hydroxy)methyl)-1-hydroxy-4-cyclopent-2-enecarboxylate (11b)

IR (neat): 3424 (br), 2957 (w), 1711 (s), 1591 (m), 1487 (m), 1438 (m), 1244 (s), 1198 (m), 1170 (m), 1082 (m), 911 (m), 789 (m), 758 (m), 731 (m), 702 (m) cm^{-1} .

Diastereomer A: ^1H NMR (CDCl_3 , 400 MHz): δ = 7.29–7.35 (m, 1H), 7.13–7.18 (m, 1H), 7.07 (dt, J = 9.7, 2.0 Hz, 1H), 6.97–7.03 (m, 2H), 5.96 (s, 1H), 3.80 (s, 3H), 2.93 (d, J = 18.4 Hz, 1H), 2.65 (d, J = 18.4 Hz, 1H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 204.0 (C), 173.9 (C), 162.9 (CF, d, J = 244 Hz), 154.4 (CH), 149.2 (C), 142.7 (C, d, J = 7 Hz), 130.3 (CH, d, J = 8 Hz), 122.4 (CH, d, J = 3 Hz), 115.2 (CH, d, J = 21 Hz), 113.6 (CH, d, J = 22 Hz), 77.1 (C), 68.8 (CH, m), 54.0 (CH_3), 48.2 (CH_2). ^{19}F NMR (CDCl_3 , 376 MHz): δ = -112.4 (s). *Diastereomer B*: ^1H NMR (CDCl_3 , 400 MHz): δ = 7.29–7.35 (m, 1H), 7.13–7.18 (m, 1H), 7.11 (dt, J = 9.7, 2.0 Hz, 1H), 6.97–7.03 (m, 2H), 5.98 (s, 1H), 3.82 (s, 3H), 2.96 (d, J = 18.4 Hz, 1H), 2.62 (d, J = 18.4 Hz, 1H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 204.0 (C), 173.9 (C), 162.9 (CF, d, J = 244 Hz), 154.1 (CH), 149.1 (C), 142.7 (d, J = 7 Hz), 130.3 (CH, d, J = 8 Hz), 122.2 (CH, d, J = 3 Hz), 115.2 (CH, d, J = 21 Hz), 113.5 (CH, d, J = 22 Hz), 77.2 (C), 68.8 (CH, m), 54.0 (CH_3), 48.3 (CH_2). ^{19}F NMR (CDCl_3 , 376 MHz): δ = -112.2 (s).

HRMS (ES): m/z [$\text{M} - \text{OH}$] $^+$ calcd for $\text{C}_{14}\text{H}_{12}\text{FO}_4$: 263.0714; found: 263.0737.

Methyl 1-hydroxy-3-(hydroxy(2-methoxypyrimidin-5-yl)methyl)-4-oxocyclopent-2-enecarboxylate (11c)

IR (neat): 3457 (m), 3171 (br), 1741 (s), 1713 (s), 1600 (m), 1570 (m), 1478 (s), 1407 (s), 1331 (m), 1272 (s), 1197 (m), 1168 (m), 1031 (s), 804 (m) cm^{-1} .

Diastereomer A: ^1H NMR (CDCl_3 , 400 MHz): δ = 8.53 (s, 2H), 7.12 (d, J = 1.4 Hz, 1H), 5.60 (d, J = 1.4 Hz, 1H), 4.01 (s, 3H), 3.84 (s, 3H), 2.99 (d, J = 18.4 Hz, 1H), 2.64 (d, J = 18.4 Hz, 1H), 2.17 (br s, 1H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 203.8 (C), 173.7 (C), 165.5 (C), 158.1 (2CH), 154.2 (CH), 148.3 (C), 127.1 (C), 77.2 (C), 65.6 (CH), 55.2 (CH_3), 54.1 (CH_3), 48.3 (CH_2). *Diastereomer B*: ^1H NMR (CDCl_3 , 400 MHz): δ = 8.48 (s, 2H), 7.24 (s, 1H), 5.56 (s, 1H), 3.99 (s, 3H), 3.79 (s, 3H), 3.20 (br s, 2H), 2.93 (d, J = 18.4 Hz, 1H), 2.66 (d, J = 18.4 Hz, 1H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 203.6 (C), 173.6 (C), 165.3 (C), 158.2 (2CH), 154.6 (CH), 148.7 (C), 127.3 (C), 77.2 (C), 65.1 (CH), 55.2 (CH_3), 54.0 (CH_3), 48.3 (CH_2).

HRMS (ES): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{13}\text{H}_{15}\text{N}_2\text{O}_6$: 295.0930; found: 295.0932.

Methyl 1-hydroxy-3-(hydroxy(2,3,6-trichlorophenyl)methyl)-4-oxocyclopent-2-enecarboxylate (11d)

IR (neat): 3421 (br), 2956 (w), 1712 (s), 1436 (s), 1322 (m), 1249 (s), 1192 (s), 1172 (s), 1092 (s), 1025 (m), 1010 (m), 913 (m), 912 (s), 771 (m), 731 (s) cm^{-1} .

Diastereomer A: ^1H NMR (CDCl_3 , 400 MHz): δ = 7.39 (d, J = 8.7 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 7.14 (d, J = 2.1 Hz, 1H), 6.39 (d, J = 5.2 Hz, 1H), 3.81 (s, 3H), 3.79 (s, 1H), 3.61 (d, J = 7.0 Hz, 1H), 2.95 (d, J = 18.3 Hz, 1H), 2.68 (d, J = 18.3 Hz, 1H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 202.9 (C), 174.0 (C), 154.8 (CH), 146.8 (C), 136.6 (C), 133.7 (C), 133.5 (C), 132.9 (C), 130.6 (CH), 129.5 (CH), 76.8 (C), 68.1 (CH), 53.9 (CH_3), 48.2 (CH_2). *Diastereomer B*: ^1H NMR (CDCl_3 , 400 MHz): δ = 7.32 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.20

(d, J = 2.1 Hz, 1H), 6.29 (d, J = 2.0 Hz, 1H), 4.11 (br s, 2H), 3.74 (s, 3H), 2.90 (d, J = 18.4 Hz, 1H), 2.59 (d, J = 18.4 Hz, 1H). ^{13}C NMR (CDCl_3 , 101 MHz): δ = 203.0 (C), 173.8 (C), 155.4 (CH), 147.0 (C), 136.4 (C), 133.7 (C), 132.8 (C), 130.5 (CH), 129.4 (CH), 77.0 (C), 67.7 (CH), 53.7 (CH_3), 48.2 (CH_2).

HRMS (ASAP): m/z [$\text{M} - \text{OH}$] $^+$ calcd for $\text{C}_{14}\text{H}_{10}\text{Cl}_3\text{O}_4$: 346.9645; found: 346.9650.

Funding Information

We gratefully acknowledge funding by the Royal Society (MB and IRB).

Acknowledgment

We thank Dr Andrej Batsanov (Durham University) for solving the X-ray structures.

Supporting Information

YES (this text will be updated with links prior to publication)



Primary Data

NO (this text will be deleted prior to publication)

References

- (1) (a) Lovering, F.; Bikker, J.; Humblet, C. *J. Med. Chem.* **2009**, *52*, 6752. (b) Lovering, F. *Med. Chem. Commun.* **2013**, *4*, 515. (c) Bajorath, J. *Expert Opin. Drug Disc.* **2016**, *11*, 825. (d) Kirkpatrick, P. *Nat. Rev. Drug Disc.* **2003**, *2*, 948.
- (2) (a) Li, C.-J.; Trost, B.M. *PNAS* **2008**, *105*, 13197. (b) Varma, R.S. *ACS Sustainable Chem. Eng.* **2016**, *4*, 5866. (c) Sheldon, R.A. *Green Chem.* **2016**, *18*, 3180.
- (3) (a) Anastas, P.T.; Warner, J.C. *Green Chemistry Theory and Practice*; Oxford University Press: New York, 1998. (b) Anastas, P.; Eghbali, N. *Chem. Soc. Rev.* **2010**, *39*, 301. (c) Li, C.-J.; Anastas, P.T. *Chem. Soc. Rev.* **2012**, *41*, 1413.
- (4) Baumann, M.; Baxendale, I.R.; Filipponi, P.; Hu, T. *Org. Process Res. Dev.* **2017** submitted.
- (5) (a) Veits, G.K.; Wenz, D.R.; Palmer, L.I.; St. Amant, A.H.; Hein, J.E.; de Alaniz, J.R. *Org. Biomol. Chem.* **2015**, *13*, 8465. (b) Shu, T.; Ni, Q.; Song, X.; Zhao, K.; Wu, T.; Puttreddy, R.; Rissanen, K.; Enders, D. *Chem. Commun.* **2016**, *52*, 2609. (c) Liu, G.; Shirley, M.E.; Van, K.N.; MacFarlin, R.L.; Romo, D. *Nat. Chem.* **2013**, *5*, 1049.
- (6) These structures have been deposited with the Cambridge Crystallographic Data Centre as CCDC XXXXXX (9e) and CCDC XXXXXX (9g).
- (7) Although separation of these diastereoisomers was found challenging by silica gel chromatography, fractional crystallization from solutions of structures **11** in Et₂O was found possible. The structure of **11a** has been deposited with the Cambridge Crystallographic Data Centre as CCDC XXXXX.

Biosketches

	<p>Marcus Baumann graduated from Philipps University Marburg (Germany) in 2007 and subsequently undertook PhD studies with Prof. Steven V. Ley at the University of Cambridge (UK) focusing on developing continuous flow processes for key organic transformations and natural product applications. In 2011, he was awarded a Feodor Lynen fellowship from the Alexander-von-Humboldt foundation allowing him to work with Prof. Larry E. Overman at the University of California Irvine (U.S.A.). Upon completion of this postdoctoral fellowship he returned to the UK to join Prof. Ian R. Baxendale at Durham University as a senior postdoctoral research associate where his research interests lie in the area of continuous flow approaches applied to the synthesis of various bioactive entities.</p>
	<p>Ian R. Baxendale obtained his Ph.D. under the supervision of Prof. Pavel Kocovsky at the University of Leicester. He then moved to a postdoctoral position with Prof. Steven V. Ley at the University of Cambridge, initially conducting natural product synthesis before moving into the area of solid-supported reagents and scavengers. In 2008, he was promoted to Senior Research Associate in the Department of Chemistry and then in 2009 was awarded a Royal Society University Research Fellowship, becoming a member of the faculty. In 2012, he moved to Durham to take up the Chair of Synthetic Chemistry. His research interests are the design and implementation of new enabling technologies such as flow chemical synthesis (FCS), synthesis automation methodologies (SAM), microwave reactors, and immobilized reagents and scavengers to expedite complex chemical syntheses.</p>